Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110008/S015

coflex Interlaminar Technology

Companion Spine France · Decision date May 22, 2026

FDA DECISIONP110008/S015

What did the FDA approve?

FDA records P110008/S015 as a supplement to PMA P110008, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 22, 2026.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested termination of study enrollment and subject follow-up for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P110008. Based upon the information submitted, the PMA supplement is approved.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Orthopedic
Decision date
May 22, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P110008/S015
Regulatory pathway
PMA supplement
Product code
NQO
Decision code
APPR
Decision date
May 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, spinous process spacer/plate.

Product code
NQO
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110008/S015 received

    Application receipt date recorded by FDA.

  2. P110008/S015 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P110008. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NQO

Product / regulatory recordCompanyPathwayDecision dateSource
Companion Spine France SasPMA supplementApr 1, 2026FDA
Companion Spine France SasPMA approvalDec 10, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Companion Spine France

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Immeuble Le Bridge - 5 Allee Des Acacias, Merignac Gironde, 33700

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records